Community Update: Novartis Discontinues Development of Branaplam

21 July 2021

We have received a Community update from Novartis confirming that they've made the difficult decision to discontinue the development of branaplam (also known as LMI070) for the treatment of SMA. They explain that their decision was "made as the result of rapid
advancements in the SMA treatment landscape in recent years."

As the decision was not driven by any safety or efficacy issues, Novartis are encouraging patients currently receiving branaplam through trials to continue their treatment until an alternate solution is arranged for ongoing care.

Read the community update